This clinical-stage biopharmaceutical company has seen three negative estimate revisions in the last 30 days. The Zacks Consensus Estimate has also moved lower over the same period. This implies ...
Cara Therapeutics Inc. (CARA) was a big mover last session, as the company saw its shares rise over 6% on the day. The move came on solid volume with far more shares changing hands than in a normal ...
(RTTNews) - Cara Therapeutics, Inc. (CARA) Monday announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results